Paul Tornetta, MD
Orthopaedic Surgery · Boston, MANPI 1073561973
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $16,306,799 of the $16,317,122 with a category attached, or 99.9%. Smith+Nephew accounts for 100.0% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $3,357,835, 2.2 times the $1,506,838 reported in 2019. Among orthopaedic surgery clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $50,832 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$16.3M
- Synthes GmbH$250
- Biotissue Holdings Inc.$118
Across 1 payment — averaging $96,692 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Smith+Nephew$97K
Across 8 payments — averaging $34,042 each. An ownership or investment interest held by the physician or an immediate family member.
- 4web, Inc.$272K
- Moximed, Inc$38
What the payments were for
- Royalty or licence$16,306,799100%
- Speaking & faculty fees$2500%
- Travel & lodging$7,3310%
- Food & beverage$2,7420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 318 | $16,316,755 |
| Synthes GmbH | 1 | $250 |
| Biotissue Holdings Inc. | 2 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVOS$14,345,019
- EVOS MINI$1,441,271
- TRIGEN Femoral (FAN/TAN/Meta Nail)$1,097,845
- TRIGEN$985,492
- NAVIO$337,083
- Navio Surgical System$273,031
- VLP Mini-MOD$150,359
- Peri-Loc$146,891
- D-RAD Smart Pack$88,777
- Peri-Loc VLP$63,686
- VLP-Foot$55,918
- D-RAD SMART PAK$43,135
- TRIGEN Meta-Nail$24,607
- Small Cannulated Screw System$19,303
- CANNULATED SCREWS$4,733
- TRIGEN InterTAN$273
How this compares
$16,317,122 in reported general payments places this provider in the 95th percentile of 542 orthopaedic surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Boston
- Thomas ThornhillBoston$12M
- Andrew FreibergBoston$5.9M
- Jon WarnerBoston$5.4M
- Wolfgang FitzBoston$3.7M
- John KwonBoston$663K
- Christopher ChiodoBoston$539K
- Andrew WhiteBoston$438K
- Carl TalmoBoston$315K
- Michael KainBoston$171K
- Nishant SunejaBoston$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.